Integrated Drug Discovery for Genetic Channelopathies
Ion channels act as basic excitatory or inhibitory units in the cell membranes of many tissues, and their dysfunction often results in a variety of channelopathies. Ligand-gated ion channels (LGICs) are associated with cognitive deficits, neurological disorders, and chronic and inflammatory pain. Voltage-gated ion channels (VGICs) are involved in the development and progression of cardiovascular disease, neurological disease, and cancer. Over the past few decades, a large number of drugs targeting ion channels have entered the market or are in preclinical and early clinical trials.
Ion channels are promising drug targets for the treatment of a variety of human diseases. There are data that ion channels are the second largest class of membrane protein targets for many FDA-approved drugs, following G protein-coupled receptors (GPCRs). A major advance in the field of channelopathies drug discovery has been the discovery that mutations in certain ion channels cause biophysical changes and alter sensitivity to drugs, which opens the way for the strategies of pharmacogenetics. Furthermore, the identification of disease modulators in channelopathies may be an alternative strategy to discover new druggable targets.
Fig. 1 Drug development in channelopathies. (Zhang, 2020)
Drug Development Services
Researchers at Creative Bioarray are committed to providing clients with comprehensive drug discovery services in the therapeutic management of major channelopathies in the central and peripheral nervous system, skeletal muscle, heart, kidney, and pancreas caused by mutations in ion channels such as calcium, sodium, potassium, and chloride channels. Our advanced crystal structure analysis technologies, high-throughput screening technologies, computer modeling technologies, new genetic research technologies, and animal model development technologies allow us to help our clients develop personalized therapies with higher efficacy and fewer side effects, accelerating the development of precise drugs specifically targeting the biological effects of pathogenic mutations.
We are committed to helping biopharmaceutical practitioners solve the following problems：
- Difficulty in target discovery and low conversion rate
- High pressure on drug R&D investment and risk control
- High failure rate in predicting the safety and efficacy of candidate drugs
- Difficult decision-making of drug development projects
Creative Bioarray has established a series of technology platforms such as high-throughput target screening, cell line development, and high-throughput expression, providing comprehensive drug discovery solutions, matching the needs of different stages, and accelerating the development of biological drugs.
Advantages
- Advanced technology platform
- One-stop drug development service
- Comprehensive, high-quality, and personalized technical support
With the world's leading ion channel analysis technology and drug research and development technology advantages, Creative Bioarray provides global clients with drug discovery services for genetic channelopathies. If you need our scientific services and technical support, please contact us for more details.
Reference
- Zhang, Y.; et al. Drug development in channelopathies: Allosteric modulation of ligand-gated and voltage-gated ion channels. Journal of Medicinal Chemistry, 2020, 63(24): 15258-15278.
